




Instance: composition-en-fab45178c60aa670cc4368c283b21dec
InstanceOf: CompositionUvEpi
Title: "Composition for quviviq Package Leaflet"
Description:  "Composition for quviviq Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpfab45178c60aa670cc4368c283b21dec)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - quviviq"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What QUVIVIQ is and what it is used for </li>
<li>What you need to know before you take QUVIVIQ </li>
<li>How to take QUVIVIQ </li>
<li>Possible side effects </li>
<li>How to store QUVIVIQ </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What quviviq is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What quviviq is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>QUVIVIQ contains the active substance daridorexant, which belongs to the class of medicines called 
 orexin receptor antagonists .  </p>
<p>QUVIVIQ is to treat insomnia in adults. </p>
<p>How QUVIVIQ works 
Orexin is a substance produced by the brain that helps keep you awake. By blocking the action of 
orexin, QUVIVIQ enables you to fall asleep faster and stay asleep longer, and improves your ability to 
function normally during the day. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take quviviq"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take quviviq"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take QUVIVIQ 
- if you are allergic to daridorexant or any of the other ingredients of this medicine (listed in 
section 6). 
- if you have narcolepsy, a condition that causes you to suddenly and unexpectedly fall asleep at 
any time. 
- if you are taking medicines which may increase the level of QUVIVIQ in your blood such as:</p>
<ul>
<li>oral medicines to treat fungal infections such as ketoconazole, posaconazole, 
voriconazole, itraconazole. </li>
<li>certain medicines to treat bacterial infections such as the antibiotics clarithromycin, 
josamycin, telithromycin, troleandomycin. </li>
<li>
<p>certain medicines to treat HIV infection such as ritonavir, elvitegravir, indinavir, 
saquinavir, telaprevir, danoprevir, lopinavir, nelfinavir, boceprevir.  </p>
</li>
<li>
<p>certain medicines to treat cancer such as ceritinib, idelalisib, ribociclib, tucatinib. 
Ask your doctor if the medicine you are taking prevents you from taking QUVIVIQ. </p>
</li>
</ul>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking QUVIVIQ if you:</p>
<ul>
<li>have depression or have or ever had suicidal thoughts </li>
<li>have a psychiatric disorder </li>
<li>currently take medicinal products that affect your brain such as treatments for anxiety or 
depression </li>
<li>have regularly taken drugs (except as medicines) or been addicted to drugs or alcohol  </li>
<li>have liver problems: depending on their severity, QUVIVIQ may not be recommended, or a 
lower dose might be required. </li>
<li>have breathing difficulties (such as severe obstructive sleep apnoea or severe chronic 
obstructive pulmonary disease) </li>
<li>have a history of falling and are older than 65 (because there is generally a higher risk of falling 
in patients &gt; 65). 
Your doctor may want to monitor how the medicine affects you. </li>
</ul>
<p>Tell your doctor if you get any of the following side effects while taking QUVIVIQ:</p>
<ul>
<li>sleep paralysis: a temporary inability to move or talk for up to several minutes upon awakening 
or falling asleep </li>
<li>hallucinations: seeing or hearing vivid or disturbing things that are not real upon awakening or 
falling asleep </li>
</ul>
<p>If you have depression and you experience a worsening or have thoughts of harming yourself, call 
your doctor straight away. </p>
<p>Children and adolescents 
This medicine is not for children and adolescents under 18 years of age because QUVIVIQ has not 
been tested in this age group. </p>
<p>Other medicines and QUVIVIQ 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines 
because:</p>
<ul>
<li>certain antibiotics (erythromycin, ciprofloxacin, clarithromycin, rifampicin), immuno-
suppressants (cyclosporine), antifungal agents (itraconazole), cancer treatments (ceritinib), or 
HIV treatments (ritonavir, efavirenz) can increase or decrease the level of QUVIVIQ in the 
blood. Some of these medicines may be contra-indicated with QUVIVIQ (see section  Do not 
take QUVIVIQ ). Your doctor will advise you on this. </li>
<li>certain medicines that work in your brain (e.g., diazepam, alprazolam) could interact with 
QUVIVIQ. Your doctor will advise you on this. </li>
<li>certain medicines to treat blood coagulation disorder such as dabigatran could interact with 
QUVIVIQ, which would require some precaution. Your doctor will advise you on this. </li>
<li>certain medicines to treat cardiac impairment such as digoxin could interact with QUVIVIQ, 
which would require some precaution. Your doctor will advise you on this. </li>
</ul>
<p>QUVIVIQ with food, drink and alcohol 
Drinking alcohol with QUVIVIQ can increase the risk of impaired balance and coordination. </p>
<p>Avoid grapefruit or grapefruit juice in the evening as they may increase the level of QUVIVIQ in the 
blood. </p>
<p>Pregnancy, breast-feeding and fertility 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before taking this medicine. </p>
<p>It is not known if QUVIVIQ can harm your unborn baby. </p>
<p>It is not known if QUVIVIQ passes into your breast milk. Talk to your doctor about the best way to 
feed your baby during treatment with QUVIVIQ. </p>
<p>It is not known if QUVIVIQ affects human fertility. </p>
<p>Driving and using machines 
A period of approximately 9 hours is recommended between taking QUVIVIQ and driving or using 
machines. Be cautious about driving or using machines in the morning after taking QUVIVIQ. Do not 
engage in potentially hazardous activities if you are not sure you are fully alert, especially in the first 
few days of treatment.  </p>
<p>QUVIVIQ contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium-
free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take quviviq"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take quviviq"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. </p>
<p>How much QUVIVIQ to take 
Your doctor will advise you on the dose of QUVIVIQ to take.  </p>
<p>The recommended dose is one 50-mg tablet of QUVIVIQ per night.  </p>
<p>If you have liver problems or take certain other medicines, your doctor may prescribe you a lower 
dose of one 25-mg tablet of QUVIVIQ per night. </p>
<p>The treatment duration should be as short as possible. The appropriateness of continued treatment will 
be assessed within 3 months by your doctor and periodically thereafter.  </p>
<ul>
<li>Take QUVIVIQ, one time per night, by mouth, in the half hour before going to bed at night.  </li>
<li>You can take QUVIVIQ with or without food, however it may take longer to work if you take it 
with or right after a large meal. </li>
</ul>
<p>If you take more QUVIVIQ than you should 
If you take more QUVIVIQ than you should, you may experience excessive sleepiness and muscle 
weakness. Contact your doctor straight away. </p>
<p>If you forget to take QUVIVIQ 
If you forget to take QUVIVIQ at bedtime, then you should not take it later during the night, otherwise 
you may feel drowsy in the morning. Do not take a double dose to make up for a forgotten tablet. </p>
<p>If you stop taking QUVIVIQ 
Treatment with QUVIVIQ can be stopped without a need to gradually reduce the dose, and without 
harmful effects.  </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The 
following side effects may happen with this medicine: </p>
<p>Common (may affect up to 1 in 10 people):</p>
<ul>
<li>headache </li>
<li>excessive sleepiness </li>
<li>dizziness </li>
<li>tiredness </li>
<li>feeling sick (nausea) </li>
</ul>
<p>Uncommon (may affect up to 1 in 100 people):</p>
<ul>
<li>temporary inability to move or talk (sleep paralysis) for up to several minutes while you are 
going to sleep or waking up (see section 2).  </li>
<li>seeing or hearing vivid or disturbing things that are not real (hallucinations; see section 2) </li>
</ul>
<p>Please talk to your doctor if either of these happen to you. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store quviviq"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store quviviq"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP.<br />
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer require. These measures will help to protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What QUVIVIQ contains<br />
The active substance is daridorexant. </p>
<p>QUVIVIQ 25 mg film-coated tablets<br />
Each tablet contains daridorexant hydrochloride, equivalent to 25 mg of daridorexant.  </p>
<p>QUVIVIQ 50 mg film-coated tablets<br />
Each tablet contains daridorexant hydrochloride, equivalent to 50 mg of daridorexant.  </p>
<p>The other ingredients are:<br />
Tablet cores: Mannitol (E421), microcrystalline cellulose (E460), povidone, croscarmellose sodium 
(see section 2  QUVIVIQ contains sodium ), silicon dioxide, magnesium stearate.  </p>
<p>Film coating: Hypromellose (E464), microcrystalline cellulose (E460), glycerol, talc (E553), titanium 
dioxide (E171), iron oxide red (E172), iron oxide black (E172), iron oxide yellow (E172; 50 mg 
tablets only).  </p>
<p>What QUVIVIQ looks like and contents of the pack 
Film-coated tablet (tablet) </p>
<p>QUVIVIQ 25 mg film-coated tablets<br />
Light purple, triangular tablet with 25 on one side, and  i  (Idorsia logo) on the other side. </p>
<p>QUVIVIQ 50 mg film-coated tablets<br />
Light orange, triangular tablet with 50 on one side, and  i  (Idorsia logo) on the other side. </p>
<p>QUVIVIQ is available in blister packs of 10, 20 or 30 film-coated tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Idorsia Pharmaceuticals Deutschland GmbH 
Marie-Curie-Strasse 8 
79539 L rrach 
Germany </p>
<p>Manufacturer 
Idorsia Pharmaceuticals Deutschland GmbH 
Marie-Curie-Strasse 8 
79539 L rrach 
Germany </p>
<p>PharmaKorell GmbH 
Georges-Koehler-Str. 2 
79539 L rrach 
Germany </p>
<p>This leaflet was last revised in </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-fab45178c60aa670cc4368c283b21dec
InstanceOf: CompositionUvEpi
Title: "Composition for quviviq Package Leaflet"
Description:  "Composition for quviviq Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpfab45178c60aa670cc4368c283b21dec)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - quviviq"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage QUVIVIQ </li>
<li>Sådan skal du tage QUVIVIQ </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What quviviq is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What quviviq is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>QUVIVIQ indeholder det aktive stof daridorexant, som tilhører den lægemiddelklasse, der kaldes 
“orexinreceptorantagonister".  </p>
<p>QUVIVIQ er til behandling af søvnløshed hos voksne. </p>
<p>Sådan virker QUVIVIQ 
Orexin, et stof, der produceres af hjernen og holder dig vågen. Ved at blokere virkningen af orexin, 
gør QUVIVIQ dig i stand til at falde hurtigere i søvn, sove i længere tid og forbedrer din evne til at 
fungere normalt i løbet af dagen. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take quviviq"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take quviviq"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke QUVIVIQ 
- hvis du er allergisk over for daridorexant eller et af de øvrige indholdsstoffer i daridorexant 
(angivet i pkt. 6). 
- hvis du har narkolepsi, en tilstand der gør, at du når som helst pludselig og uventet falder i søvn. 
- hvis du tager medicin, som kan øge niveauet af QUVIVIQ i blodet, som f.eks.:</p>
<ul>
<li>oral medicin til behandling af svampeinfektioner, såsom ketoconazole, posaconazole, 
voriconazole og itraconazol </li>
<li>visse lægemidler til behandling af bakteriel infektion, såsom antibiotika clarithromycin, 
josamycin, telithromycin og troleandomycin </li>
<li>visse lægemidler til behandling af hiv-infektion, såsom ritonavir, elvitegravir, indinavir, 
saquinavir, telaprevir, danoprevir, lopinavir, nelfinavir og boceprevir. </li>
<li>visse lægemidler til behandling af cancer, såsom ceritinib, idelasilib, ribociclib og 
tucatinib.  </li>
</ul>
<p>Spørg din læge, om den medicin, som du tager, forhindrer, at du kan tage QUVIVIQ. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager QUVIVIQ. </p>
<ul>
<li>Hvis du har en depression eller på noget tidspunkt har haft selvmordstanker. </li>
<li>Hvis du har en psykisk sygdom. </li>
<li>Hvis du i øjeblikket tager medicin, som påvirker din hjerne, som f.eks. behandlinger for angst 
eller depression. </li>
<li>Hvis du jævnligt har taget stoffer (undtagen som medicin), eller du har været afhængig af 
lægemidler eller alkohol.  </li>
<li>Hvis du har leverproblemer: Afhængig af styrken kan QUVIVIQ muligvis ikke anbefales, eller 
det kan være nødvendigt med en lavere dosis. </li>
<li>Hvis du har åndedrætsproblemer (som f.eks. svær kronisk obstruktiv lungesygdom) </li>
<li>Hvis du tidligere har haft tendens til at falde og du er over 65 år (fordi der generelt er en højere 
risiko for at falde hos patienter &gt; 65 år). </li>
</ul>
<p>Din læge ønsker måske at overvåge, hvordan medicinen påvirker dig. </p>
<p>Fortæl det til lægen, hvis du får nogen af følgende bivirkninger, mens du tager QUVIVIQ:</p>
<ul>
<li>Søvnparalyse: En midlertidig manglende evne til at bevæge dig eller tale i op til adskillige 
minutter, når du er ved at vågne eller er ved at falde i søvn. </li>
<li>Hallucinationer: Du ser eller hører levende eller forstyrrende ting, der ikke er virkelige, når du 
er ved at vågne eller er ved at falde i søvn. </li>
</ul>
<p>Kontakt omgående din læge, hvis du har en depression, og du oplever en forværring eller får tanker 
om selvskade. </p>
<p>Børn og unge 
Dette lægemiddel er ikke beregnet til børn og unge under 18 år, da QUVIVIQ ikke er testet på denne 
aldersgruppe. </p>
<p>Brug af andre lægemidler sammen med QUVIVIQ 
Fortæl altid lægen eller på apoteket, hvis du tager andre lægemidler, for nylig har taget andre 
lægemidler eller planlægger at tage andre lægemidler.  </p>
<ul>
<li>Visse antibiotika (erythromycin, ciprofloxacin, clarithromycin, rifampicin), 
immunundertrykkende midler (cyclosporin), svampedræbende midler (itraconazol), cancer-
behandlinger (ceritinib), eller hiv-behandlinger (ritonavir, efavirenz) kan øge eller reducere 
niveauet af QUVIVIQ i blodet. Nogle af disse lægemidler kan være kontraindicerede med 
QUVIVIQ (se afsnittet ’Brug ikke QUVIVIQ’). Din læge vil rådgive dig om dette. </li>
<li>Visse lægemidler, der virker i hjernen (f.eks. diazepam, alprazolam), kan interagere med 
QUVIVIQ. Din læge vil rådgive dig om dette. </li>
<li>Visse lægemidler til behandling af blodkoagulationsforstyrrelser, såsom dabigatran, kan 
interagere med QUVIVIQ, hvilket kræver en vis forsigtighed. Din læge vil rådgive dig om 
dette. </li>
<li>Visse lægemidler til behandling af hjertesvigt, såsom digoxin, kan interagere med QUVIVIQ, 
hvilket vil kræve en vis forsigtighed. Din læge vil rådgive dig om dette. </li>
</ul>
<p>Brug af QUVIVIQ sammen med mad, drikke og alkohol 
Indtagelse af alkohol sammen med QUVIVIQ kan øge risikoen for nedsat balanceevne eller 
koordination. </p>
<p>Undgå grapefrugt eller grapefrugtjuice om aftenen, da det kan øge niveauet af QUVIVIQ i blodet. </p>
<p>Graviditet, amning og frugtbarhed 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du tager dette lægemiddel. </p>
<p>Det vides ikke, om QUVIVIQ kan skade dit ufødte barn. </p>
<p>En lille mængde QUVIVIQ passerer ind i modermælken. Tal med lægen om den bedste måde at 
ernære dit barn på under behandling med QUVIVIQ. </p>
<p>Det vides ikke, om QUVIVIQ påvirker frugtbarheden hos mennesker. </p>
<p>Trafik og arbejdssikkerhed 
Der anbefales et tidsrum på ca. 9 timer mellem indtagelse af QUVIVIQ og inden der føres 
motorkøretøjer eller betjenes maskiner. Vær forsigtig med at føre motorkøretøjer eller betjene 
maskiner om morgenen, efter du har taget QUVIVIQ. Undlad at udføre potentielt farlige aktiviteter, 
hvis du ikke er sikker på, at du er helt opmærksom, særligt i løbet af de første dage med behandling. </p>
<p>QUVIVIQ indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg) pr. tablet, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take quviviq"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take quviviq"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Så meget QUVIVIQ, skal du tage 
Din læge vil rådgive dig med hensyn til dosisstørrelsen af QUVIVIQ.  </p>
<p>Den anbefalede dosis er én 50 mg tablet med QUVIVIQ pr. nat.  </p>
<p>Hvis du har leverproblemer eller tager visse andre lægemidler, kan din læge ordinere en lavere dosis 
på én 25 mg tablet QUVIVIQ pr. nat. </p>
<p>Behandlingsvarigheden skal være så kort som muligt. Relevansen af fortsat behandling vil evalueres af 
din læge inden for 3 måneder og derefter jævnligt. </p>
<ul>
<li>Tag QUVIVIQ 1 gang pr. nat gennem munden en halv time før du går i seng om aftenen.  </li>
<li>Du kan tage QUVIVIQ med eller uden mad. Det kan imidlertid være længere om at virke, hvis 
du tager det umiddelbart efter et stort måltid. </li>
</ul>
<p>Hvis du har taget for meget QUVIVIQ 
Hvis du har taget for meget QUVIVIQ, kan du opleve overdreven døsighed og muskelsvaghed. 
Kontakt omgående din læge. </p>
<p>Hvis du har glemt at tage QUVIVIQ 
Hvis du glemmer at tage QUVIVIQ ved sengetid, skal du ikke tage den senere i løbet af natten, da du 
kan komme til at føle dig døsig om morgenen. Du må ikke tage en dobbeltdosis som erstatning for den 
glemte tablet. </p>
<p>Hvis du holder op med at tage QUVIVIQ 
Behandlingen med QUVIVIQ kan stoppes uden det er nødvendigt at nedsætte dosis gradvist og uden 
skadelige virkninger. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. 
Følgende bivirkninger kan forekomme med dette lægemiddel: </p>
<p>Almindelige (kan forekomme hos 1 ud af 10 personer):</p>
<ul>
<li>Hovedpine </li>
<li>Overdreven døsighed </li>
<li>Svimmelhed </li>
<li>Træthed </li>
<li>Kvalme </li>
</ul>
<p>Ikke almindelige (kan forekomme hos 1 ud af 100 personer):</p>
<ul>
<li>midlertidig manglende evne til at bevæge sig eller tale (søvnparalyse) i op til adskillige minutter 
under indsovning eller opvågning (se pkt. 2).  </li>
<li>at se eller høre levende eller forstyrrende ting, der ikke er virkelige (hallucinationer; se pkt. 2). </li>
</ul>
<p>Tal med din læge, hvis du oplever nogen af disse ting. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store quviviq"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store quviviq"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Tag ikke dette lægemiddel efter den udløbsdato, der står på beholderen og blisterkortet efter “EXP".<br />
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du 
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden.  </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>QUVIVIQ indeholder<br />
Aktivt stof/aktive stoffer: daridorexant. </p>
<p>QUVIVIQ 25 mg filmovertrukne tabletter<br />
Hver tablet indeholder daridorexanthydrochlorid, der svarer til 25 mg daridorexant.  </p>
<p>QUVIVIQ 50 mg filmovertrukne tabletter<br />
Hver tablet indeholder daridorexanthydrochlorid, der svarer til 50 mg daridorexant.  </p>
<p>Øvrige indholdsstoffer:<br />
Tabletkerner: mannitol (E421), mikrokrystallinsk cellulose (E460), povidon, natriumcroscarmellose 
(se pkt. 2, “QUVIVIQ indeholder natrium"), siliciumdioxid, magnesiumstearat.  </p>
<p>Filmovertræk: Hypromellose (E464), mikrokrystallinsk cellulose (E460), glycerol, talkum (E553), 
titaniumdioxid (E171), jernoxid rød (E172), jernoxid sort (E172), jernoxid gul (E172; kun 50 mg 
tabletter).  </p>
<p>Udseende og pakningsstørrelser 
Filmovertrukken tablet (tablet) </p>
<p>QUVIVIQ 25 mg filmovertrukne tabletter<br />
Lysviolet, trekantet tablet med 25 på den ene side og ‘i’ (Idorsia-logo) på den anden side. </p>
<p>QUVIVIQ 50 mg filmovertrukne tabletter<br />
Lysorange, trekantet tablet med 50 på den ene side og ‘i’ (Idorsia-logo) på den anden side. </p>
<p>QUVIVIQ leveres i blisterpakninger med 10, 20 eller 30 filmovertrukne tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Idorsia Pharmaceuticals Deutschland GmbH 
Marie-Curie-Strasse 8 
79539 Lörrach 
Tyskland </p>
<p>Fremstiller 
Idorsia Pharmaceuticals Deutschland GmbH 
Marie-Curie-Strasse 8 
79539 Lörrach 
Tyskland </p>
<p>PharmaKorell GmbH 
Georges-Koehler-Str. 2 
79539 Lörrach 
Tyskland </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-fab45178c60aa670cc4368c283b21dec
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for quviviq Package Leaflet for language en"
Description: "ePI document Bundle for quviviq Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-fab45178c60aa670cc4368c283b21dec"
* entry[0].resource = composition-en-fab45178c60aa670cc4368c283b21dec

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpfab45178c60aa670cc4368c283b21dec"
* entry[=].resource = mpfab45178c60aa670cc4368c283b21dec
                            
                    
Instance: bundlepackageleaflet-da-fab45178c60aa670cc4368c283b21dec
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for quviviq Package Leaflet for language da"
Description: "ePI document Bundle for quviviq Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-fab45178c60aa670cc4368c283b21dec"
* entry[0].resource = composition-da-fab45178c60aa670cc4368c283b21dec

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpfab45178c60aa670cc4368c283b21dec"
* entry[=].resource = mpfab45178c60aa670cc4368c283b21dec
                            
                    



Instance: mpfab45178c60aa670cc4368c283b21dec
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product QUVIVIQ 25 mg film-coated tablets"
Description: "QUVIVIQ 25 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/22/1638/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "QUVIVIQ 25 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: fab45178c60aa670cc4368c283b21decListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "quviviq"

* status = #current
* mode = #working

* title = "List of all ePIs associated with quviviq"

* subject = Reference(mpfab45178c60aa670cc4368c283b21dec)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#quviviq "quviviq"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-fab45178c60aa670cc4368c283b21dec) // quviviq en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-fab45178c60aa670cc4368c283b21dec) // quviviq da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-fab45178c60aa670cc4368c283b21dec
InstanceOf: List

* insert fab45178c60aa670cc4368c283b21decListRuleset
    